<DOC>
	<DOCNO>NCT03005873</DOCNO>
	<brief_summary>This trial Phase IIa , Randomized , Double blind , Placebo control , Dose find Study investigate safety efficacy TLC599 subject osteoarthritis knee .</brief_summary>
	<brief_title>A Phase IIa , Randomized , Double Blinded , Placebo Controlled , Dose Finding Study Single Dose Administration TLC599 Patients With Osteoarthritis ( OA ) Knee</brief_title>
	<detailed_description>Protocol No : TLC599A2003 Name Finished Product : TLC599 Title Study : A Phase IIa , Randomized , Double blind , Placebo control , Dose find Study Single dose Administration TLC599 Patients Osteoarthritis ( OA ) Knee . Study duration : The trial last around 27 week include 21-day screening period 24-week follow-up period .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>Main 1 . Male female patient , least 50 year age . 2 . Documented diagnosis OA knee least 6 month 3 . The study knee OA Grade 2 3 severity base Kellgren Lawrence grade 4 . Patients patient related visual analogue scale ( VAS ) score 5.0 9.0 baseline . 5 . Willing able comply study procedure provide write informed consent . Main 1 . Patients receive systemic corticosteroid within last 30 day prior dose . 2 . Patients use prohibited medication within 7 day prior study drug administration pain control medication include acetaminophen within 48 hour prior study drug administration . 3 . Patients use prohibited medication acetaminophen oral NSAIDs screen visit 7 day prior study drug administration . 4 . Documented history confirm autoimmune disease 5 . History posttraumatic knee arthritis , evidence intra articular bleeding study knee 6 . History infective arthritis 7 . Unstable study knee joint 8 . Use IA corticosteroid , hyaluronic acid , IA injection study knee within 3 month prior screen visit . 9 . A history treat malignancy disease free ≤ 5 year prior screen visit 10 . Uncontrolled unstable concurrent medical psychiatric illness , jeopardize safety patient 11 . Use chemotherapeutic systemic immunosuppressant agent inflammatory disease within 6 month prior screen visit . 12 . Current use anticoagulant , include warfarin , heparin , low molecular weight heparin , dabigatran . 13 . Abnormalities laboratory parameter describe qualify exclusion : hemoglobin &lt; 8 g/dL ; total white blood cell count &lt; 4000/ µL ; serum bilirubin/ alanine aminotransferase/ aspartate aminotransferase &gt; 2 time upper limit normal ( ULN ) laboratory reference range ; serum creatinine &gt; 2 time ULN laboratory reference range ; serum uric acid &gt; ULN laboratory reference range ; prothrombin time/International Normalized Ratio &gt; ULN laboratory reference range . 14 . Contraindication undergo magnetic resonance imaging ( MRI )</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>osteoarthritis knee</keyword>
	<keyword>TLC599</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>DSP</keyword>
</DOC>